Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533104 | 0.93 | NR1I2 (0.50) | NR1I2 | |
| SCHEMBL20533106 | 0.92 | — | — | |
| SCHEMBL20533637 | 0.91 | NR1I2 (0.59) | NR1I2 | |
| SCHEMBL20533112 | 0.90 | — | — | |
| SCHEMBL20533129 | 0.89 | NR1I2 (0.47) | NR1I2 | |
| SCHEMBL20533294 | 0.87 | NR1I2 (0.56) | NR1I2 | |
| Choline SCHEMBL20533128 | 0.87 | — | — | |
| SCHEMBL20533223 | 0.85 | — | — | |
| SCHEMBL20533118 | 0.85 | — | — | |
| SCHEMBL20533160 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136301-B2 | Broad spectrum antiviral compounds and uses thereof | The Regents of the University of California, A California Corporation et al. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136301-B2 | Broad spectrum antiviral compounds and uses thereof | The Regents of the University of California, A California Corporation et al. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20180297963-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF MIAMI | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136301-B2 | Broad spectrum antiviral compounds and uses thereof | MAVS, EIF2AK2, ZC3HAV1 | NR1I2 3617/4885 |
| US-20180297963-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, EIF2AK2, ZC3HAV1 | NR1I2 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.